MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Disease Types: Colon, Solid Tumors

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

For More Information:

clinicaltrials.gov- Petosemtamab trial